We then tested SV2A expression by immunohistochemistry on cytospins from a panel of TRAMP-derived prostate cancer cell lines (T1525, T23, and ST4787) generated in our laboratory [Ref (9) and Supplementary Figure 1], and on in vitro-cultured bone marrow-derived MCs (BMMCs). The gene discussed is SV2A; the disease is prostate carcinoma.